SELENOK-Dependent CD36 Palmitoylation Regulates Microglial A
2026-05-07
SELENOK-Dependent CD36 Palmitoylation Regulates Microglial Aβ Clearance
Study Background and Research Question
Alzheimer’s disease (AD) is defined neuropathologically by extracellular amyloid-beta (Aβ) deposits and intracellular neurofibrillary tangles, with Aβ playing a central role in triggering neurodegenerative cascades. Despite intensive research, significant therapeutic breakthroughs remain elusive. Epidemiological and experimental work implicates selenium (Se) deficiency as a risk factor for AD, but the molecular mechanisms by which Se exerts neuroprotection—particularly via selenoproteins—are incompletely understood (paper). This study probes the specific role of selenoprotein K (SELENOK) in microglial immune regulation, focusing on its control of CD36 palmitoylation and the subsequent impact on Aβ phagocytosis and pathology in AD.Key Innovation from the Reference Study
The central innovation lies in delineating a mechanistic axis: SELENOK regulates the palmitoylation of the scavenger receptor CD36 via the palmitoyltransferase DHHC6, which is critical for proper CD36 localization to the plasma membrane of microglia. This localization, in turn, governs the cells’ ability to recognize and clear Aβ. The study reveals that loss of SELENOK impairs CD36 palmitoylation, reduces microglial Aβ uptake, and exacerbates cognitive deficits in animal models. Importantly, selenium supplementation restores SELENOK expression and CD36 palmitoylation, improving microglial phagocytic function and mitigating AD progression. This mechanistic link from dietary Se to selenoprotein function and microglial Aβ clearance had not been previously established (paper).Methods and Experimental Design Insights
The authors employed both in vivo and in vitro models:- Genetic Models: SELENOK knockout (KO) mice, as well as 5xFAD transgenic mice (a robust AD model), to dissect genetic dependencies.
- Overexpression Strategies: Viral AAV vectors for SELENOK overexpression in the brain to rescue observed deficits.
- Palmitoylation Assays: Acyl-biotin exchange (ABE) and chemical labeling approaches to detect and quantify CD36 palmitoylation.
- Functional Assays: Phagocytosis assays using fluorescently labeled Aβ (FAM-Aβ42), migration assays, and measurements of microglial activation.
- Patient and Animal Tissue Analysis: Western blotting, immunohistochemistry, and gene expression profiling to assess protein and RNA levels in brains from AD patients and mouse models.
- Selenium Supplementation: Dietary or in vitro supplementation to examine reversibility and mechanistic specificity.
Protocol Parameters
- assay | Acyl-biotin exchange (ABE) | 1–3 mg/mL protein lysate | detection of palmitoylated CD36 in brain and microglial samples | enables quantitative comparison of palmitoylation status | paper
- assay | FAM-Aβ42 phagocytosis | 1 μM FAM-Aβ42, 4 h incubation | quantification of microglial Aβ uptake | directly measures functional consequence of CD36 palmitoylation | paper
- buffer pH | 7.4 (PBS) | optimal for thiol-reactive labeling and protein stability | preserves native protein conformation and thiol accessibility | workflow_recommendation
- selenium supplementation | 0.2–0.5 ppm in animal feed | restoration of SELENOK and CD36 palmitoylation | reflects physiologically relevant dietary Se levels | paper
- protein biotinylation reagent | 0.5–2 mM Biotin-HPDP in DMSO | thiol-specific labeling for palmitoylation detection | compatible with disulfide exchange-based biotin capture workflows | workflow_recommendation
Core Findings and Why They Matter
SELENOK as a Regulator of Microglial Function: SELENOK deficiency in microglia led to impaired migration, reduced Aβ phagocytosis, and worsened cognitive deficits in 5xFAD mice. Restoration of SELENOK expression reversed these phenotypes (paper).CD36 Palmitoylation Mechanism: The study shows that SELENOK promotes CD36 palmitoylation via the DHHC6 palmitoyltransferase. Palmitoylation is critical for CD36’s localization to the microglial plasma membrane, enabling effective Aβ recognition and clearance.
Human and Animal Relevance: Reduced CD36 palmitoylation was documented in both AD patient brains and AD mouse models, supporting clinical significance. Selenium supplementation upregulated SELENOK and enhanced microglial Aβ clearance in vivo, providing a mechanistic rationale for selenium’s neuroprotective effects (paper).
Comparison with Existing Internal Articles
Recent internal reviews (e.g., Biotin-HPDP: Catalyzing Redox-Driven Discovery) have emphasized the importance of thiol-specific protein labeling for redox biology and neurodegeneration studies. Biotin-HPDP (N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide) is highlighted as a key reagent for reversible biotinylation of cysteine-containing proteins, enabling workflows such as the biotin switch assay for detection of S-palmitoylation and S-nitrosylation (Precision Thiol-Specific Protein Labeling). The present paper’s focus on CD36 palmitoylation in microglia directly aligns with these technical advances, as detection and quantification of palmitoylation status often depend on thiol-reactive biotinylation reagents. Internal articles underscore the workflow flexibility and sensitivity offered by reagents like Biotin-HPDP, which complement the mechanistic discoveries in the reference study by enabling robust analysis of protein modifications in complex samples.Limitations and Transferability
While the study provides compelling evidence for SELENOK’s role in regulating microglial Aβ phagocytosis via CD36 palmitoylation, several limitations should be noted:- Specificity: The regulatory axis is established in microglia; broader implications for other CNS cell types or peripheral macrophages remain to be explored.
- Therapeutic Translation: The reversal of AD phenotypes via selenium supplementation is shown in animal models; human clinical relevance will require cautious extrapolation and further validation.
- Palmitoylation Detection: The accuracy and quantification of palmitoylation are contingent on biochemical assay sensitivity and specificity, which can be affected by sample preparation or reagent choice (internal review).